The Problem of SARS-CoV-2 Resistance to Antiviral Drugs (Review and Own Experience)
Tuberculosis, Lung Diseases, HIV Infection · 06.11.2026 · (4) · 70-78
DOI: 10.30978/tb2026-4-70 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tuberculosis, Lung Diseases, HIV Infection, online erschienen am 06.11.2026. Verfasst von O.A. Golubovska und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-ND 4.0).
Abstract (Originalsprache)
The introduction of antiviral drugs into clinical practice has substantially improved clinical outcomes in patients with COVID-19. However, the genetic variability of SARS-CoV-2 facilitates the emergence of resistance to antiviral medicines, potentially reducing treatment efficacy. Objective — to analyse the effectiveness of current antiviral drugs for the treatment of COVID-19 in the context of SARS-CoV-2 variability in order to optimise patient care. Materials and methods. A literature review was performed on the probability and frequency of the development of SARS-CoV-2 resistance to antiviral medicines with different mechanisms of action used for the treatment of COVID-19. A retrospective analysis of the medical records of patients who were hospitalised in infectious disease departments in Kyiv and received antiviral therapy was conducted. Results and discussion. The mechanisms of SARS-CoV-2 mutations that may lead to the emergence of viral resistance to modern antiviral drugs (remdesivir, molnupiravir, nirmatrelvir/ritonavir) and monoclonal antibodies were analysed based on published literature. Persistence of antiviral-resistant viral variants, which is more likely in immunocompromised individuals, may lead to the spread of the virus in the population. Our clinical experience with the effectiveness of monoclonal antibodies and direct-acting antiviral drugs in patients with COVID-19 indicates that their administration early in the course of the disease contributes to faster regression of clinical manifestations, a reduction in the frequency of progression to severe disease and in mortality. However, even under these conditions, the success of etiotropic therapy is not guaranteed due to the potential for pathogen resistance to the drug. Conclusions. The literature suggests that prolonged SARS-CoV-2 persistence, particularly in immunocompromised patients, increases the likelihood of viral mutations, which may potentially contribute to the development of pathogen resistance to antiviral drugs. The results of our observations indicate the importance of early initiation of antiviral therapy; however, its effectiveness may be insufficient due to pathogen resistance to the drug.
Zitieren
APA
Golubovska, O., Shestakova, I., Gudzenko, O., Mytus, N., Kondratiuk, L., & Bezrodna, O. (2026). The Problem of SARS-CoV-2 Resistance to Antiviral Drugs (Review and Own Experience). Tuberculosis, Lung Diseases, HIV Infection, 70-78. https://doi.org/10.30978/tb2026-4-70
Vancouver
Golubovska O, Shestakova I, Gudzenko O, Mytus N, Kondratiuk L, Bezrodna O. The Problem of SARS-CoV-2 Resistance to Antiviral Drugs (Review and Own Experience). Tuberculosis, Lung Diseases, HIV Infection. 2026:70-78. doi:10.30978/tb2026-4-70
BibTeX
@article{Golubovska2026,
author = {Golubovska, O.A. and Shestakova, I.V. and Gudzenko, O.A. and Mytus, N.V. and Kondratiuk, L.O. and Bezrodna, O.V.},
title = {The Problem of SARS-CoV-2 Resistance to Antiviral Drugs (Review and Own Experience)},
journal = {Tuberculosis, Lung Diseases, HIV Infection},
year = {2026},
number = {4},
pages = {70--78},
doi = {10.30978/tb2026-4-70}
}
EUVIMED